L50.8 L20.9 C84.0 L28.1 L12.0 L92.0 L13.0 L50.8
Conditions
Interventions
Group 1: In patients with atopic dermatitis, mycosis fungoides, Prurigo nodularis, bullous Pemphigoid, Granuloma anulare, Dermatitis herpetiformis and chronic urticaria clinicals scores of disease sev
Sponsors
Charite-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie
Eligibility
Sex/Gender
All
Age
18 Years to 90 Years
Inclusion criteria
Inclusion criteria: Diagnosis: Patients with any of the following skin diseases will be included in the study, either prospectively or retrospectively: • Chronic spontaneous urticaria • Atopic dermatitis • Prurigo • Bullous pemphigoid • Mycosis fungoides • Granuloma anulare • Dermatitis herpetiformis • Healthy controls Key inclusion criteria: • Adults (18 years or older) • Able to read, understand and willing to sign the informed consent form and abide with study procedures •Willing, committed and able to complete all study-related procedures • Patients may have additional concomitant disease, but only one dominant skin disease. • No participation in other clinical trials 4 weeks before in this study
Exclusion criteria
Exclusion criteria: • Concurrent/ongoing treatment with immunosuppressives (e.g. cyclosporine, methotrexate, dapsone or others) within 4 weeks or 5 half lives prior to study entry whichever is longer • Prior or concurrent treatment with oral or systemic Corticosteroids within last 4 weeks, • Prior or concurrent treatment with topical Corticosteroids within last 2 weeks at the sites of skin biopsy. • Concurrent/ongoing treatment with Omomalizumab within 3 months prior to study entry • Prior or concurrent treatment with Mepolizumab or Resilizumab. • Significant medical condition rendering the patient immunocompromised or not suitable for a clinical trial • Lactating females or pregnant females • Enrollment in another investigational treatment or device study or use of an investigational agent, or less than 4 weeks or 5 half-lives, whichever is longer, since end of another investigational device or drug trial • Subjects for whom there is concern about compliance with the protocol procedures • Any medical condition which, in the opinion of the Investigator, would interfere with participation in the study or place the subject at risk • Subjects who are detained officially or legally to an official institute • Intake of leukotriene antagonists within 7 days prior to study entry • History of hypersensitivity/allergy to local anesthetics • History of substance abuse (drug or alcohol) or any other factor (e.g., serious psychiatric condition) that could limit the subject’s ability to comply with study procedures.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Determination of IL-5R and eosinophil’s levels of expression in the skin samples of the various diseases (comparison lesional and non-lesional skin) and in comparison with skin samples of healthy controls. | — |
Secondary
| Measure | Time frame |
|---|---|
| Correlation of the cutaneous IL-5R and eosinophil's levels of expression with disease activity, duration, other demographic and clinical parameters, presence and intensity of itching and blood levels of IL-5, IL-5R, eosinophils and eosinophilic cationic protein. | — |
Countries
Germany
Contacts
Public ContactSabine Altrichter
Charite-Universitätsmedizin Berlin, Klinik für Dermatologie und Allergologie
Outcome results
None listed